Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms

Neuroscience

Volumn 123, Issue 4, 2004, Pages 967-981

  Hebb, A L O ^a   Robertson, H A ^a   Denovan Wright, E M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

in situ hybridization; Northern blot; PDE10A; PDE1B; PDE4A; Western blot

Indexed keywords

MESSENGER RNA; PHOSPHODIESTERASE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE STRAIN; MULTIGENE FAMILY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; STRIATE CORTEX; SYMPTOMATOLOGY; TRANSGENIC MOUSE; WILD TYPE;

EID: 1642441418     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2003.11.009     Document Type: Article

References (79)

1. Ambrose C.M., Duyao M.P., Barner G., Bates G.P., Lin C.S., Srinidhi J., Baxendale S., Hummerich H., Lehrach H., Altherr M. Structure and expression of the Huntington's disease gene evidence agonist simple inactivation due to an expanded CAG repeat . Somat Cell Mol Genet. 20:1994;27-38.
2. Barbeau A. Progress in understanding Huntington's chorea. Can J Neurol Sci. 2:1975;81-85.
3. Beavo J. Cyclic nucleotide phosphodiesterase functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
4. Bhide P.G., Day M., Sapp E., Scharz C., Sheth A., Kim J., Young A.B., Penney J., Golden J., Aronin N., DiFiglia M. Expression of normal and mutant huntingtin in the developing brain. J Neurosci. 16:1996;5523-5535.
5. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int J Impot Res. 8:1996;47-52.
6. Bowes C., Li T., Danciger M., Baxter L.C., Applebury M.L., Farber D.B. Retinal degeneration in the rd mouse is caused by a defect in the B subunit of rod cGMP-phosphodiesterase. Nature. 347:1990;677-680.
7. Brandt J., Butters N. The neuropsychology of Huntington's disease. Trends Neurosci. 9:1986;118-120.
8. Brown R.G., Marsden C.D. 'Subcortical dementia' the neuropsychological evidence . Neuroscience. 25:1988;363-387.
9. Caine E.D., Hunt R.D., Weingartner H., Ebert M.H. Huntington's dementia clinical and neuropsychological features . Arch Gen Psychiatry. 35:1978;377-384.
10. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 19:1999;3248-3257.
11. Cha J.-H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23:2000;387-392.
12. Cha J.-H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA. 95:1998;6480-6485.
13. Challiss R.A., Nicholson C.D. Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br J Pharm. 99:1990;47-52.
14. Cicchetti F., Prensa L., Wu Y., Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Rev. 34:2000;80-101.
15. Conti M., Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucl Acid Res Mol Biol. 63:1999;1-38.
16. Coyle J.T. An animal model of Huntington's disease. Biol Psychiatry. 14:1979;251-276.
17. Denovan-Wright EM, Gilby KL, Howlett SE, Robertson HA (2000) PCR 5: differential display: a practical approach. In: Cloning of differentially expressed brain cDNAs (Leslie R, Robertson HA, eds), pp 131-158. Oxford, UK: Oxford University Press.
18. Denovan-Wright E.M., Newton R.A., Armstrong J.N., Babity J.M., Robertson H.A. Acute administration of cocaine, but not amphetamine, increases the level of synaptotagmin IV mRNA in the dorsal striatum of rat. Mol Brain Res. 55:1998;350-354.
19. Denovan-Wright E.M., Robertson H.A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience. 98:2000;705-713.
20. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.-P., Carraway R., Reeves S.A., Boyce F.M., Aronin N. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14:1995;1075-1081.
21. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-604.
22. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 269:1995;407-410.
23. Franklin KBJ, Paxinos G (1997) The mouse brain atlas. Academic Press.
24. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases relating structure and function . Prog Nucl Acid Res Mol Biol. 65:2000;1-52.
25. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 274:1999;18438-18445.
26. Fujishige K., Kotera J., Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A . Eur J Biochem. 266:1999;1118-1127.
27. Fujishige K., Kotera J., Yuasa K., Omori K. The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains . Eur J Biochem. 267:2000;5943-5951.
28. Furuyama T., Iwashashi Y., Tano Y., Takagi H., Inahaki S. Localization of 63 kDa calmodulin-stimulated phosphodiesterase mRNA in the rat brain by in situ hybridization histochemistry. Mol Brain Res. 26:1994;331-336.
29. Giembycz M.A. Cilomilast a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease . Exp Opin Invest Drugs. 10:2001;1361-1379.
30. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Gen. 12:2003;497-508.
31. Goldberg Y.P., Kalchman M.A., Metzler M., Nasir J., Zeisler J., Graham R., Koide H.B., O'Kusky J., Sharp A.H., Ross C.A., Jirik F., Hayden M.R. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. Hum Mol Gen. 5:1996;177-185.
32. Graveland G.A., Williams R.S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science. 227:1985;770-773.
33. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 14:2001;1492-1504.
34. Harper P.S. The epidemiology of Huntington's disease. Hum Gen. 89:1992;365-376.
35. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell. 72:1993;971-983.
36. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.R., Aronin N., DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem. 277:2002;7466-7476.
37. Koide R., Ikeuchi T., Onodera O., Tanaka H., Igarashi S., Endo K., Takahashi H., Kondo R., Ishikawa A., Hayashi T., Saoito M., Tomoda A., Miike T., Naito H., Ikuta F., Tsuji S. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet. 6:1994;9-13.
38. Li S.-H., Cheng A.L., Li H., Li X.-J. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J Neurosci. 19:1999;5159-5172.
39. Li S.-H., Cheng A.L., Zhou H., Lam S., Rao M., Li H., Li X.-J. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol. 22:2002;1277-1287.
40. Liu Y.F. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem. 273:1998;28873-28877.
41. Lloyd K.G. The neuropathology of GABA neurons in extrapyramidal disorders. J Neural Trans Suppl. 16:1980;217-227.
42. Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K., Florio V.A. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene. 234:1999;109-117.
43. Ludlow C.L., Connor N.P., Bassich C.J. Speech timing in Parkinson's and Huntington's disease. Brain Lang. 32:1987;195-214.
44. Luthi-Carter R., Strand A., Petters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.-H., Olson J.A. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Gen. 9:2000;1259-1271.
45. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S., Bates G. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
46. Meade C.A., Deng Y.P., Fusco F.R., Del Mar N., Hersch S., Goldowitz D., Reiner A. Cellular localization and development of neuronal intranuclear inclusions. J Comp Neurol. 29:2002;241-269.
47. Metzler M., Chen N., Helgason C.D., Graham R.K., Nichol K., McCutcheon K., Nasir J., Humphries R.K., Raymond L.A., Hayden M.R. Life without huntingtin normal differentiation into functional neurons . J Neurochem. 72:1999;1009-1018.
48. Monckton D.G., Caskey C.T. Unstable triplet repeat diseases. Circulation. 91:1995;513-520.
49. Moreland R.B., Goldstein I., Kim N.N., Traish A. Sildenafil citrate, a selective phosphodiesterase 5 inhibitor. Trends Endocrinol Metab. 10:1999;97-104.
50. Perutz M.F. Glutamine repeats as polar zippers their possible role in inherited neurodegenerative diseases . Proc Natl Acad Sci USA. 91:1994;5355-5358.
51. Perutz M.F. Glutamine repeats and inherited neurodegenerative diseases molecular aspects . Curr Opin Struct Biol. 6:1996;848-858.
52. Polli J.W., Kincaid R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci. 14:1994;1251-1261.
53. Reed T.M., Repaske D.R., Snyder G.L., Greengard P., Vorhees C.V. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci. 22:2002;5188-5197.
54. Reiner A., Albin R.L., Anderson K.D., D'Amato C.S., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci USA. 85:1988;5733-5737.
55. Richfield E.K., O'Brien C.F., Eskin T., Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett. 132:1991;121-126.
56. Ross C.A. When more is less pathogenesis of glutamine repeat neurodegenerative diseases . Neuron. 15:1995;493-496.
57. Sanborn B.M., Heindel J.J., Robinson G.A. The role of cyclic nucleotides in reproductive processes. Annu Rev Physiol. 42:1980;37-57.
58. Sánchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 421:2003;373-379.
59. Sharp A.H., Love S.J., Schilling G., Li S.-H., Li X.-J., Bao J., Wagster M.V., Kotzuk J.A., Steiner J.P., Lo A., Hedreen J., Sisodia S., Snyder S.H., Dawson T.M., Ryugo D.K., Ross C.A. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14:1995;1065-1074.
60. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family PDE10A . Proc Natl Acad Sci USA. 96:1999;7071-7076.
61. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling new phosphodiesterases and new functions . Curr Opin Cell Biol. 12:2000;174-179.
62. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1:1995;244-248.
63. Stott K., Blackburn J.M., Butler P.J.G., Perutz M. Incorporation of glutamine repeats makes protein oligomerize implications for neurodegenerative diseases . Proc Natl Acad Sci USA. 92:1995;6509-6513.
64. Trottier Y., Biancalana V., Mandel J.L. Instability of CAG repeats in Huntington's disease relation to parental transmission and age of onset . J Med Genet. 31:1994;377-382.
65. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E.C., Mandel J. Cellular localization of the Huntington Disease protein and discrimination of the normal and mutant form. Nat Genet. 10:1995;104-110.
66. Truss M.C., Stief C.G., Uckert S., Becker A.J., Wefer J., Schultheiss D., Jonas U. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction from bench to bedside . World J Urol. 19:2001;344-350.
67. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature. 404:2000;721-722.
68. van Roon-Mom W.M., Reid S.J., Jones A.L., MacDonald M.E., Faull R.L., Snell R.G. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain Res Mol Brain Res. 109:2002;1-10.
69. van Staveren W.C.G., Markerink-van Ittersum M., Steinbusch H.W.M., de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res. 888:2001;275-286.
70. Velier J., Kim M., Schwarz C., Kim T.W., Sapp E., Chase K., Aronin N., DiFiglia M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol. 152:1998;34-40.
71. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol. 44:1985;559-567.
72. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet. 17:1997;404-410.
73. Ye Y., Conti M., Houslay M.D., Farooqui S.M., Chen M., O'Donnell J.M. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem. 69:1997;2397-2404.
74. Ye Y., Jackson K., O'Donnell J.M. Effects of repeated antidepressant treatment on type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem. 74:2000;1257-1262.
75. Ye Y., O'Donnell J.M. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem. 66:1996;1894-1902.
76. Young A.B., Penney J.B., Starosta-Rubinstein S., Markel D.S., Berent S., Giordani B., Ehrenkaufer R., Jewett D., Hichwa R. PET scan investigations of Huntington's disease cerebral metabolic correlates of neurological features and functional decline . Ann Neurol. 20:1986;296-303.
77. m, cyclic AMP-specific phosphodiesterase in rat brain. Dev Brain Res. 112:1999;11-19.
78. m, cyclic AMP-specific phosphodiesterase in rat brain. Dev Brain Res. 116:1999;181-189.
79. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 23:2000;217-247.